Skip to main content
. Author manuscript; available in PMC: 2015 Nov 1.
Published in final edited form as: Lung Cancer. 2014 Aug 17;86(2):237–240. doi: 10.1016/j.lungcan.2014.08.007

Table 3.

Comparison of Grade 3 and 4 Toxicity with Different Dosing Regimens of Temozolomide

5-day regimen (N=25)
N (%)
21-day regimen (N=64)
N (%)
Thrombocytopenia 4 (16) 6 (10)
Neutropenia 2 (8) 3 (5)
Anemia 1 (4) 2 (3)
Fatigue 0 (0) 2 (3)
Rash 0 (0) 2 (3)
Constipation 1 (4) 0 (0)